Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Abu Farha, Mohamed ^a   Behbehani, Kazem ^a   Elkum, Naser ^a  

^a DASMAN DIABETES INSTITUTE   (Kuwait)

Author keywords

Adipokine; Adiponectin; Adipsin; Arab; Cardiometabolic risk factors; hsCRP; Leptin; Lipid profile; Low grade inflammation; Metabolic syndrome; Resistin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT FACTOR D; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARAB; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; KUWAIT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION RESEARCH; SYSTOLIC BLOOD PRESSURE;

ADIPOKINES; ADULT; ARABS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 84899483130     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-76     Document Type: Article

References (58)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127(1):e6-e245. 10.1161/CIR.0b013e31828124ad, 23239837.
2. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013, 216(1):T17-T36. 10.1530/JOE-12-0232, 23160967.
3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56(14):1113-1132. 10.1016/j.jacc.2010.05.034, 20863953.
4. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165(21):2479-2484. 10.1001/archinte.165.21.2479, 16314544.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20):1615-1622. 10.1001/jama.279.20.1615, 9613910.
6. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491):1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
7. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, Tremoli E, Kooistra T, Morange PE, Lundman P, Mohamed-Ali V, Hamsten A. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53(7):852-857. 10.1016/j.metabol.2004.02.004, 15254876.
8. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54(9):1847-1856. 10.1007/s10620-008-0585-3, 19052866.
9. Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost 2013, 110(4):641-650. 10.1160/TH13-03-0212, 23846791.
10. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010, 2010:513948. 2874930, 20508843.
11. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380(1-2):24-30. 2755046, 17343838.
12. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006, 26(10):2200-2207. 10.1161/01.ATV.0000242905.41404.68, 16931789.
13. Pereira RI, Wang CC, Hosokawa P, Dickinson LM, Chonchol M, Krantz MJ, Steiner JF, Bessesen DH, Havranek EP, Long CS. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures. BMC Endocr Disord 2011, 11:13. 10.1186/1472-6823-11-13, 3141565, 21736747.
14. Khan UI, Wang D, Sowers MR, Mancuso P, Everson-Rose SA, Scherer PE, Wildman RP. Race-ethnic differences in adipokine levels: the Study of Women's Health Across the Nation (SWAN). Metabolism 2012, 61(9):1261-1269. 10.1016/j.metabol.2012.02.005, 3404256, 22444780.
15. Chin KH, Sathyasurya DR, Abu Saad H, Jan Mohamed HJ. Effect of ethnicity, dietary intake and physical activity on plasma adiponectin concentrations among malaysian patients with type 2 diabetes mellitus. Int J Endocrinol Metab 2013, 11(3):167-174. 3860115, 24348588.
16. Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM. Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol 2013, 12:170. 10.1186/1475-2840-12-170, 24225161.
17. Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV, Franke AA, Wilkens LR, Hernandez BY, Goodman MT, Henderson BE, Kolonel LN, Le Marchand L, Maskarinec G. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond) 2014, doi:10.1038/ijo.2014.25.
18. Hajat C, Harrison O, Al Siksek Z. Weqaya: a population-wide cardiovascular screening program in Abu Dhabi, United Arab Emirates. Am J Public Health 2012, 102(5):909-914. 10.2105/AJPH.2011.300290, 21940918.
19. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
20. Santaniemi M, Ukkola O, Malo E, Bloigu R, Kesaniemi YA. Metabolic syndrome in the prediction of cardiovascular events: The potential additive role of hsCRP and adiponectin. Eur J Prev Cardiol 2013, doi:10.1177/2047487313494028.
21. Ford ES, Schulze MB, Pischon T, Bergmann MM, Joost HG, Boeing H. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol 2008, 7:35. 10.1186/1475-2840-7-35, 2627822, 19077281.
22. Kelliny C, William J, Riesen W, Paccaud F, Bovet P. Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovasc Diabetol 2008, 7:27. 10.1186/1475-2840-7-27, 2556312, 18801172.
23. Chiu FH, Chuang CH, Li WC, Weng YM, Fann WC, Lo HY, Sun C, Wang SH. The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults. Cardiovasc Diabetol 2012, 11:40. 10.1186/1475-2840-11-40, 3471043, 22533665.
24. Lu B, Zhang S, Wen J, Yang Y, Yang Z, Zhang Z, Wang X, Hu R. The New Unified International Diabetes Federation/American Heart Association/National Heart, Lung, and Blood Institute Metabolic Syndrome definition: does it correlate better with C-reactive protein in Chinese patients diagnosed with type 2 diabetes?. J Int Med Res 2010, 38(6):1923-1932. 10.1177/147323001003800605, 21226995.
25. Zuo H, Shi Z, Yuan B, Dai Y, Wu G, Hussain A. Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS One 2013, 8(1):e54615. 10.1371/journal.pone.0054615, 3551759, 23349940.
26. Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf) 2011, 203(1):259-269. 10.1111/j.1748-1716.2010.02237.x, 3110567, 21281456.
27. Cale JM, Lawrence DA. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 2007, 8(9):971-981. 10.2174/138945007781662337, 17896949.
28. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2(8549):3-9.
29. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996, 94(9):2057-2063. 10.1161/01.CIR.94.9.2057, 8901651.
30. Panahloo A, Mohamed-Ali V, Gray RP, Humphries SE, Yudkin JS. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene. Atherosclerosis 2003, 168(2):297-304. 10.1016/S0021-9150(03)00095-9, 12801613.
31. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342(24):1792-1801. 10.1056/NEJM200006153422406, 10853003.
32. Festa A, D'Agostino R, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999, 19(3):562-568. 10.1161/01.ATV.19.3.562, 10073958.
33. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 1987, 13(3 Pt 2):331-336.
34. Chou YY, Sheu WH, Tang YJ, Chen YM, Liao SC, Chuang YW, Lin CS, Chen DY. Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. Arch Gerontol Geriatr 2009, 49(Suppl 2):S41-S45.
35. Hashimoto N, Kanda J, Nakamura T, Horie A, Kurosawa H, Hashimoto T, Sato K, Kushida S, Suzuki M, Yano S, Iwai R, Takahashi H, Yoshida S. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 2006, 55(12):1653-1657. 10.1016/j.metabol.2006.08.005, 17142139.
36. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23(1):85-89. 10.1161/01.ATV.0000048856.22331.50, 12524229.
37. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47(6):1108-1116. 10.1161/01.HYP.0000222368.43759.a1, 16651465.
38. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291(14):1730-1737. 10.1001/jama.291.14.1730, 15082700.
39. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr 2009, 4(1):44-49. 10.1111/j.1559-4572.2008.00030.x, 19245516.
40. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003, 3(3):207-213. 10.1007/s11892-003-0065-2, 12762967.
41. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51(2):536-540. 10.2337/diabetes.51.2.536, 11812766.
42. Kotani K, Saiga K, Kurozawa Y, Sakane N, Tsuzaki K, Hamada T. Adiponectin I164T gene polymorphism and the obesity-related effects on the Japanese female population. Clin Chim Acta 2007, 384(1-2):182-183.
43. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, Bertelli M, Fanin E, Andrighetto G, Federspil G, Vettor R. Increased serum resistin in adults with prader-willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005, 90(7):4335-4340. 10.1210/jc.2005-0293, 15870134.
44. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005, 52(5):519-524. 10.1507/endocrj.52.519, 16284427.
45. Saddi-Rosa P, de Oliveira CS V, Crispim F, Giuffrida FM, de Lima VC, Vieira JG, Doria A, Velho G, Reis AF. Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovasc Diabetol 2013, 12(1):119. 10.1186/1475-2840-12-119, 3765274, 23968400.
46. Maresh JG, Shohet RV. In vivo endothelial gene regulation in diabetes. Cardiovasc Diabetol 2008, 7:8. 10.1186/1475-2840-7-8, 2365940, 18423039.
47. Lee SE, Kim HS. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012, 48(1):27-35. 10.1540/jsmr.48.27, 22504487.
48. Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011, 10(1):13. 10.1186/1475-2840-10-13, 3039566, 21276223.
49. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012, 11:132. 10.1186/1475-2840-11-132, 3499352, 23101436.
50. Mente A, Razak F, Blankenberg S, Vuksan V, Davis AD, Miller R, Teo K, Gerstein H, Sharma AM, Yusuf S, Anand SS. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care 2010, 33(7):1629-1634. 10.2337/dc09-1392, 2890372, 20413520.
51. Silha JV, Nyomba BL, Leslie WD, Murphy LJ. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 2007, 30(2):286-291. 10.2337/dc06-1073, 17259496.
52. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism 2004, 53(1):1-3. 10.1016/j.metabol.2003.07.002, 14681833.
53. Gardener H, Crisby M, Sjoberg C, Hudson B, Goldberg R, Mendez AJ, Wright CB, Rundek T, Elkind MS, Sacco RL. Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord 2013, 11(1):46-55. 10.1089/met.2012.0065, 3593695, 23127161.
54. Zadjali F, Al-Yahyaee S, Hassan MO, Albarwani S, Bayoumi RA. Association of adiponectin promoter variants with traits and clusters of metabolic syndrome in Arabs: family-based study. Gene 2013, 527(2):663-669. 10.1016/j.gene.2013.06.057, 23845780.
55. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Hussain T, Yakout S, Vinodson B, Sabico S. Adiponectin gene polymorphisms (T45G and G276T), adiponectin levels and risk for metabolic diseases in an Arab population. Gene 2012, 493(1):142-147. 10.1016/j.gene.2011.11.045, 22155316.
56. Mtiraoui N, Ezzidi I, Turki A, Chaieb A, Mahjoub T, Almawi WY. Single-nucleotide polymorphisms and haplotypes in the adiponectin gene contribute to the genetic risk for type 2 diabetes in Tunisian Arabs. Diabetes Res Clin Pract 2012, 97(2):290-297. 10.1016/j.diabres.2012.02.015, 22497971.
57. Rizk NM, El-Menyar A, Marei I, Sameer M, Musad T, Younis D, Farag F, Basem N, Al-Ali K, Al Suwaidi J. Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology 2013, 64(4):257-265. 10.1177/0003319712455497, 22887729.
58. Juanola-Falgarona M, Salas-Salvado J, Estruch R, Portillo MP, Casas R, Miranda J, Martinez-Gonzalez MA, Bullo M. Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol 2013, 12:7. 10.1186/1475-2840-12-7, 3558443, 23298335.